According to filings with the U.S. Securities and Exchange Commission, Thrombolex is raising up to $4,839,829.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Michael Cerminaro played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Thrombolex
At Thrombolex, Inc. our goal is to create a continuous stream of new products based on the original BASHIR platform technology, which will improve the treatment outcomes for patients suffering from acute VTE conditions, by creating innovative endovascular catheters for use in the treatment of patients with acute venous thromboembolic (VTE) conditions. Our vision for success is to orchestrate the medical professions identified unmet needs with our unique product development capabilities.

To learn more about Thrombolex, visit http://www.thrombolex.com/

Contact:
Michael Cerminaro, Chief Financial Officer
844-792-6300
https://www.linkedin.com/in/michael-j-cerminaro-6b732410/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.